Patients
NPC and disease progression, Cancer
ONCOLOGY, CANCER
This single arm, phase II trial (ClinicalTrials.gov: NCT03906058) enrolled patients aged 18–70 years with pathologically confirmed locally recurrent or metastatic NPC and disease progression after at least two lines of prior systemic treatments. Patients had to have adequate organ function, an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, and at least one measurable lesion per RECIST v1.1. Patients were excluded if they had received prior treatment with bevacizumab or VEGFR inhibitors or had received re-irradiation at nasopharyngeal lesions. Detailed eligibility criteria are described in the study protocol.The trial was conducted according to the provisions of the Declaration of Helsinki and the International Conference on Harmonisation guidelines for Good Clinical Practice and approved by the institutional review board of Sun Yat-Sen University Cancer Center. All patients provided written informed consent before enrollment. The study protocol adhered to the SPIRIT statement and the reporting of the study adhered to the CONSORT statement.